FDA Updates Dupilumab Label Supporting Use Among Atopic Derm

The updated labeling for dupilumab’s use resulted from the first phase 3 trial assessing a biologic within this subgroup of eczema patients.

Related Keywords

Georged Yancopoulos , Naimish Patel , Regen Regeneron Pharmaceuticals Inc , Drug Administration , Regen Regeneron Pharmaceuticals , Chief Scientific Officer , Atopic Dermatitis , Eczema , Dupilumab , Labeling , Hand , Foot , Fda ,